Matsumoto, Kinnosuke
Shiroyama, Takayuki
Tamiya, Motohiro
Minami, Toshiyuki
Kinehara, Yuhei
Tamiya, Akihiro
Suga, Yasuhiko
Kuge, Tomoki
Mori, Masahide
Suzuki, Hidekazu
Tobita, Satoshi
Ueno, Kiyonobu
Namba, Yoshinobu
Tetsumoto, Satoshi
Niki, Toshie
Morimura, Osamu
Osa, Akio
Nishino, Kazumi
Nagatomo, Izumi
Takeda, Yoshito
Kijima, Takashi
Kumanogoh, Atsushi
Funding for this research was provided by:
Osaka University
Article History
Received: 21 September 2023
Accepted: 4 November 2023
First Online: 4 January 2024
Declarations
:
: Dr. A. Tamiya reports receiving grants from AstraZeneca, BeiGene, and Daiichi-Sankyo; and honoraria for lectures from AstraZeneca, Boehringer Ingelheim, Eli Lilly, Pfizer, Amgen, Kyowa Kirin, Merck BioFarma, Novartis, Ono Pharmacaceutical, Chugai Pharmacaceutical, Bristol-Myers Squibb, Taiho Pharmaceutical, Merck Sharp & Dohme, Takeda Pharmaceutical, Nihon-Kayaku, and Thermo Fischer Scientific outside of the submitted work. Dr. M. Tamiya reports receiving grants from Ono Pharmaceutical, Japan, Bristol-Myers Squibb, and Boehringer Ingelheim; and honoraria for lectures from Taiho Pharmaceutical, Japan, Eli Lilly, Asahi Kasei Pharmaceutical, Merck Sharp & Dohme, Boehringer Ingelheim, AstraZeneca, Chugai Pharmaceutical, Ono Pharmaceutical, and Bristol-Myers Squibb outside of the submitted work. Dr. Nishino reports receiving grants from Ono Pharmaceutical, Taiho Pharmaceutical, Merck Sharp & Dohme, AbbVie, Daiichi-Sankyo, Amgen, Eisai, Sanofi, Janssen Pharmaceutical, Novartis, Pfizer, Eli Lilly Japan, Merck Biopharma, Takeda Pharmaceutical, Chugai Pharmaceutical, Merus; and honoraria for lectures from AstraZeneca, Chugai pharmaceutical, Nippon Boehringer Ingelheim, Eli Lilly Japan, Roche Diagnostics, Novartis, Pfizer, Merk, Janssen Pharmaceutical, Bristol-Myers Squibb, Nippon Kayaku outside of the submitted work. Dr. Mori. reports receiving grants from Ono Pharmaceutical, Merck Sharp & Dohme, Delt-Fly Pharma, Chugai Pharmaceutical; and honoraria for lectures from AstraZeneca, Chugai pharmaceutical, Nippon Boehringer Ingelheim, Eli Lilly Japan, Novartis, Pfizer, Merck Sharp & Dohme, Bristol-Myers Squibb, Ono Pharmaceutical, Taiho Pharmaceutical, Takeda Pharmaceutical, Nippon Kayaku, Kyowa Kirin, Daiichi-Sankyo, Otsuka Pharmaceutical, Shionogi Pharmaceutical outside of the submitted work. Dr. Kijima. reports receiving honoraria for lectures from Chugai pharmaceutical, Bristol-Myers Squibb, Ono Pharmaceutical outside of the submitted work. The other authors declare no conflicts of interest.
: This cohort study was conducted in accordance with the Declaration of Helsinki and the World Health Organization’s Guidelines for Good Clinical Practice. This study was also approved by the ethical review board of each participating institute. An opt-out method was used so that patients and families could refuse to participate in the study.